Co
Corvus (Angel)
Burlingame CAFounded 201430 employees
Private CapbiotechAcquiredOncology
Platform: A2aR Adenosine
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Polainavolisib | COR-5864 | Phase 2/3 | 1 | FcRn | MDDET | ||
| COR-2320 | COR-2320 | Preclinical | 2 | WEE1 | CTCLOCD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)